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Impact of Sequence Variation in the UL128 Locus on Production of
Human Cytomegalovirus in Fibroblast and Epithelial Cells
Isa Murrell,a Peter Tomasec,a Gavin S. Wilkie,b Derrick J. Dargan,b Andrew J. Davison,b Richard J. Stantona
Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdoma; MRC–University of Glasgow Centre for Virus Research, Glasgow,
United Kingdomb
The human cytomegalovirus (HCMV) virion envelope contains a complex consisting of glycoproteins gH and gL plus proteins
encoded by the UL128 locus (UL128L): pUL128, pUL130, and pUL131A. UL128L is necessary for efficient infection of myeloid,
epithelial, and endothelial cells but limits replication in fibroblasts. Consequently, disrupting mutations in UL128L are rapidly
selected when clinical isolates are cultured in fibroblasts. In contrast, bacterial artificial chromosome (BAC)-cloned strains
TB40-BAC4, FIX, and TR do not contain overt disruptions in UL128L, yet no virus reconstituted from them has been reported to
acquire mutations in UL128L in vitro. We performed BACmutagenesis and reconstitution experiments to test the hypothesis
that these strains contain subtle mutations in UL128L that were acquired during passage prior to BAC cloning. Compared to
strainMerlin containing wild-type UL128L, all three strains produced higher yields of cell-free virus. Moreover, TB40-BAC4 and
FIX spread cell to cell more rapidly than wild-typeMerlin in fibroblasts but more slowly in epithelial cells. The differential
growth properties of TB40-BAC4 and FIX (but not TR) were mapped to single-nucleotide substitutions in UL128L. The substitu-
tion in TB40-BAC4 reduced the splicing efficiency of UL128, and that in FIX resulted in an amino acid substitution in UL130.
Introduction of these substitutions intoMerlin dramatically increased yields of cell-free virus and increased cell-to-cell spread in
fibroblasts but reduced the abundance of pUL128 in the virion and the efficiency of epithelial cell infection. These substitutions
appear to represent mutations in UL128L that permit virus to be propagated in fibroblasts while retaining epithelial cell tropism.
Human cytomegalovirus (HCMV) is ubiquitous throughoutpopulations worldwide and represents a significant public
health challenge in both developed and developing countries (1).
Like other herpesviruses, HCMV establishes life-long persistent
infections with periodic episodes of reactivation that require con-
stant immunosurveillance. Productive infection is commonly
asymptomatic in an immunocompetent host, but the virus re-
mains a leading infectious cause of congenital malformation and
is responsible for a broad spectrum of pathological consequences
in immunocompromised (e.g., AIDS patients) or immunosup-
pressed individuals (e.g., transplant recipients). HCMV displays
tropism for a broad range of cell types and tissues in vivo, with
disease being associated with most major organs. For example,
initial infection occurs in mucosal epithelial tissues, infection of
endothelial tissues can result in transfer of virus to solid organs
and leukocytes for dissemination, and CD34 bone marrow pro-
genitor cells and monocytes are sites of latency (1–3). Thus, stud-
ies of HCMV pathogenesis require the use of virus with the ability
to infect a wide range of cell types in vitro. However, there are
significant challenges associated with in vitro propagation of virus
that exhibits the broad tropism characteristic of clinical virus.
Classically, three distinct virion envelope glycoprotein com-
plexes, designated gCI, gCII, and gCIII, have been implicated in
recognition and uptake of HCMV by the cell. gCI, composed of
glycoprotein gB, and gCII, composed of glycoproteins gMand gN,
mediate the initial attachment of virions. Both are capable of bind-
ing to heparin sulfate proteoglycans (4–7), while gB is also capable
of binding to integrins, epidermal growth factor receptor (EGFR),
and platelet-derived growth factor receptor  (PDGFR). All of
thesemolecules have been reported to be important for virus entry
(8–11), although the roles of EGFR and PDGFR have been dis-
puted (12, 13). Following initial binding, fusion with cellular
membranes is orchestrated by gB and gCIII, which is formed of
glycoproteins gH, gL, and gO (14–18). More recently it has be-
come apparent that gH and gL also form a second glycoprotein
complex, and that infection of different cell types occurs by differ-
ent mechanisms involving these two different complexes.
Infection of fibroblasts occurs by direct fusion of the virion
envelope with the plasmamembrane, whereas in epithelial, endo-
thelial, and myeloid cells, membrane fusion takes place in vesicles
following internalization by endocytosis ormicropinocytosis (19–
22). gH/gL/gO is required for infection, virionmaturation, egress,
and cell-to-cell spread in fibroblasts, as well as for infection of
epithelial and endothelial cells (6, 23, 24). A second complex, gH/
gL/UL128L, is formed by gH/gL along with the products of the
UL128 locus (UL128L), pUL128, pUL130, and pUL131A. gH/gL/
UL128L is required for efficient infection and cell-to-cell spread in
epithelial, endothelial, and myeloid cells (22, 25–35), either by
binding to cell surface receptors (22, 27, 28) or by promoting
nuclear translocation of virions (21, 32, 36). Infection of fibro-
blasts does not require gH/gL/UL128L; in fact, virus containing
gH/gL/UL128L displays reduced cell-to-cell spread and cell-free
release in fibroblasts in vitro (37, 38). As a result, there is consid-
erable selection pressure against UL128L in this cell type. Thus,
routine isolation of HCMV strains from clinical material in fibro-
blasts is associated with rapid acquisition of disabling mutations
in UL128L, which are usually apparent as frameshifts caused by
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insertion or deletion of one or more nucleotides, in-frame termi-
nation codons caused by single-nucleotide substitutions, or dele-
tions (37–44). This results in the generation of laboratory-adapted
viruses that display efficient growth in fibroblasts but limited
growth in other cell types.
To provide a genetically stable source of HCMV, the genome
can be cloned into a bacterial artificial chromosome (BAC) and
virus recovered by transfection (38, 45–47). However, HCMV is
invariably subjected to some degree of passaging in vitro prior to
BAC cloning, and as a result, BAC-cloned strains exhibit various
degrees of in vitro adaptation. We have previously described the
cloning of the complete HCMV strain Merlin genome into a self-
excising BAC following five passages in fibroblasts (38). In vitro-
acquired mutations were identified by reference to the original
clinical material and repaired, with the resulting BAC having the
genetic competence of wild-type virus. However, as with clinical
HCMV strains, the presence of wild-typeUL128L in reconstituted
virus results in the production of very low titers of cell-free virus in
vitro, and the virus is prone to mutation when passaged in fibro-
blasts (38).
Several HCMV strains in addition to Merlin have been BAC
cloned. These include TB40-BAC4, which was cloned from a
mixed population of TB40/E following five passages in fibroblasts
and 22 passages in endothelial cells (48), FIX, which was derived
from strain VR1814 following 46 passages in fibroblasts (49, 50),
and TR, which was isolated from an ocular swab from an AIDS
patient (51, 52). Strains TB40-BAC4, FIX, and TR were cloned by
replacing sequences in one region of the genome (at the left end of
Us) with a nonexcising BAC vector. UL128L in each BAC is ap-
parently intact, and reconstituted virus is able to infect epithelial
and endothelial cells. However, unlike strains isolated from clini-
cal material, there are no reports of viruses reconstituted from
these BACs acquiring mutations in UL128L during passage in
vitro. This raised the hypothesis that these viruses contain subtle
mutations in UL128L that were acquired during passage of the
clinical isolates prior to BAC cloning. Indeed, our study identifies
single-nucleotide substitutions in strains TB40-BAC4 and FIX
that impact UL128 andUL130, respectively. Introduction of these
substitutions into wild-type UL128L in strainMerlin dramatically
increased yields of cell-free virus and increased cell-cell spread in
fibroblasts but reduced both the abundance of pUL128 in the
virion and the efficiency of infection in epithelial cells.
MATERIALS AND METHODS
Cells and viruses. Primary human fetal foreskin fibroblast (HFFF) cells
and human telomerase reverse transcriptase (hTERT)-immortalized ret-
inal pigmented epithelial (RPE-1) cells were grown in Dulbecco’s modi-
fied Eaglemedium (DMEM) (Life Technologies) supplemented with fetal
bovine serum (10%, vol/vol), penicillin (500 U/ml), and streptomycin
(500 g/ml) at 37°C in 5% CO2. Two variants of the Merlin BAC were
used and have been described previously (38). Merlin-UL128Lmut (previ-
ously called pAL1158) contains a premature stop codon in UL128, while
Merlin-UL128Lwt (previously called pAL1160) containswild-typeUL128.
Both BACs contain a frameshift in RL13 and an internal ribosomal entry
site (IRES) followed by enhanced green fluorescent protein (EGFP) after
UL122. TB40-BAC4was kindly donated by Christian Sinzger (48), FIX by
Gabi Hahn (50), and TR by Jay Nelson (51). For these BACs, recom-
bineering was used to insert an IRES followed by EGFP after UL122 as
described previously (38). HCMV strain 3301 DNA had been extracted
previously from the urine of a congenitally infected infant (40).
Infections were performed at 37°C for 2 h on a rocker, followed by
removal of the inoculum and addition of fresh medium (53). In titrations
and assays to investigate cell-to-cell spread, supernatant-driven spread
was limited by use of a 1%Avicel semisolid overlay (54). After incubation
for 14 days (for fibroblasts) or 21 days (for epithelial cells), the overlay was
removed and cells were washed in phosphate-buffered saline (PBS). Un-
less otherwise stated, quantitation of cell-free virus produced during in-
fection of both fibroblast and epithelial cells was performed using HFFF,
since this is the only cell type in which all viruses could infect and spread.
Plaques were identified based on EGFP expression and imaged using an
ORCA-ER camera and Leica DMIRBE microscope. Plaque sizes were de-
termined using OpenLab 3 software.
Preparation of BACs. Stocks of each BAC-cloned genome were pre-
pared using a Nucleobond plasmid purification kit (Macherey-Nagel) ac-
cording to themanufacturer’s instructions. The concentration of purified
plasmid DNA was determined by use of an ND1000 spectrophotometer
(Nanodrop).
Transfections. BACs were transfected into HFFF cells by electropora-
tion using a Nucleofector (Amaxa) and basic fibroblast kit (Lonza) and
programT-16 according to themanufacturer’s instructions.Onoccasions
when themonolayer formedwas less than 70% confluent on the following
day, additional cells were added. The number of plaques formed following
electroporation varied only marginally, ranging from 20 to 35 per trans-
fection. RPE-1 cells were transfected using Effectene (Qiagen) according
to themanufacturer’s instructions. The number of plaques formed varied
only minimally, with 50 to 70 plaques generated per transfection. These
variations were not observed to have amajor impact on the relative rate of
virus spread through the monolayer in experimental repeats.
FACS analysis. At weekly time points posttransfection, infected
RPE-1 cultures were trypsinized and reseeded into fresh flasks. An aliquot
of cells was kept for fluorescence-activated cell sorter (FACS) analysis
using an Accuri C6 and CFlow software for the detection of EGFP cells.
Recombineering. All recombineering was performed as described
previously (38, 55, 56), using E. coli SW102 cells containing the BAC to be
modified. A selectable amp/sacB/lacZ cassette was PCR amplified and in-
serted into the region to be modified, followed by positive selection for
expression of ampicillin resistance on medium supplemented with ampi-
cillin (50 g/ml). In a second round of recombineering, the selection
cassette was swapped with the DNA sequence to be inserted, followed by
negative selection onmedium supplemented with sucrose (5%, wt/vol) to
select against sacB expression and 5-bromo-4-chloro-3-indolyl--d-ga-
lactopyranoside (X-Gal) and isopropyl -d-1-thiogalactopyranoside
(IPTG) to identify white colonies lacking lacZ expression. Amplification
of the selectable cassette was performed using the Expand HiFi system
(Roche) under the following conditions: 95°C for 2min; 10 cycles at 95°C
for 30 s, 55°C for 30 s, and 68°C for 4.5min; 25 cycles at 95°C for 30 s, 55°C
for 30 s, and 68°C for 4.5 min; and 68°C for 15 min. Primer pairs were
designed with approximately 20 bp of identity to the selectable cassette at
each 3= end and approximately 80 bp of identity to sequences adjacent to
the insertion site at the 5= end. In the primer sequences shown below,
regions identical to sequences immediately up- and downstream from the
insertion site are underlined. Primers were designed to cover regions with
100% identity in all strains.
Insertion of UL128L sequences into the Merlin genome. For inser-
tion of the complete UL128L from strains TR, TB40-BAC4, FIX, and 3301
in place of the wild-type Merlin UL128L, the amp/sacB/lacZ cassette was
amplified using primers SacBR-131A (CAG TCT GCA ACA TGC GGC
TGT GTC GGG TGT GGC TGT CTG TTT GTC TGT GCG CCG TGG
TGC TGG GTC AGT GCC AGC GGG ACT GAG GTT CTT ATG GCT
CTT G) and SacBF-128 (ATC CAG CCG TTT GTG TTT CTT AAC GCT
CTC CAG GTA CTG ATC CAG GCC CAC GAT CCG GGT TAT CTT
GTC GTA TTC CAG CCT GTG ACG GAA GAT CAC TTC G). UL128L
from each strain was amplified using a Phusion high-fidelity kit (New
EnglandBioLabs) and primersUL128LF (GCGTATTTCGGACAAACA
CAC A) and UL128LR (CGC ATG TTG CAG ACT GAG AAA GA). PCR
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was performed under the following conditions: 98°C for 1 min; 35 cycles
at 98°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and 72°C for 10 min.
Insertion of the unique TB40-BAC4 nucleotide into the Merlin ge-
nome. The amp/sacB/lacZ selection cassette was amplified using primers
SacBF (GGT GGT GAC GAT CCC GCG AAT CTC AGC CGT TTT CTC
GGG ACT GTA GCA GAC TTC GCC GTC CGG ACA CCG CAG CCT
GTG CCT GTG ACG GAA GAT CAC TTC G) and SacBR (CTG GAT
CTG TCT CTC GAC GTT TCT GAT AGC CAT GTT CCA TCG ACG
ATC CTC GGG AAT GCC AGA GTA GAT TTT CAT GAA TCT GAG
GTT CTT ATG GCT CTT G). The following oligonucleotide was used to
insert the TB40-BAC4 UL128 nucleotide (underlined): GTT TTC TCG
GGA CTG TAG CAG ACT TCG CCG TCC GGA CAC CGC AGC CTG
TTG ATT CAT GAA AAT CTA CTC TGG CAT TCC CGA GGA TCG
TCG ATG GAA CAT G.
Insertion of unique FIX UL130 nucleotide into the Merlin genome.
The amp/sacB/lacZ selection cassette was amplified using primers SacBF-
FIX (GTC TGG CCT TCC CGG TTG TAC AGC AGA TAC AGG GTC
TCG TTG CGA CAC TCG GGA CCC GTT GAT ACC CGC TGG AAC
CCCCCTGTGACGGAAGATCACTTCG) and SacBR-FIX (TATTCC
AAA CCG CAT GAC GCG GCG ACG TTT TAC TGT CCT TTT CTC
TAT CCC TCG CCC CCA CGA TCC CCC TTG CAA TTC CCT GAG
GTT CTT ATG GCT CTT G). The following oligonucleotide was used to
insert the FIXUL130 nucleotide (underlined): AGGGTCTCGTTGCGA
CAC TCG GGA CCC GTT GAT ACC CGC TGG AAC CCC GAT AAT
TGC AAG GGG GAT CGT GGG GGC GAG GGA TAG AGA AAA GGA
CAG TAA A.
Sanger DNA sequencing.UL128L was amplified by PCR using prim-
ers UL128LF (GCG TAT TTC GGA CAA ACA CAC A) and UL128LR
(CGC ATG TTG CAG ACT GAG AAA GA). UL128L was amplified from
all viruses during time courses (e.g., from infected cell culture superna-
tants) to determine whether it retained its original sequence. The Advan-
tage II PCR system (Clontech) was used according to the manufacturer’s
instructions under the following conditions: 95° for 10 min; 35 cycles at
95°C for 30 s, 55°C for 30 s, and 68°C for 3 min; and 68°C for 10 min.
When UL128L was amplified from a BAC, the HiFi expand PCR system
(Roche) was used according to the manufacturer’s instructions under the
following conditions: 94°C for 2min; 30 cycles at 94°C for 15 s, 68°C for 30
s, and 72°C for 2 min; and 72°C for 7 min. PCR products were purified
from agarose gels by using an Illustra GFX PCR DNA gel band purifica-
tion kit (GE Healthcare) and then sequenced (EurofinsMWG) using the
primers CGG ATT GTA GTT GCA GCT CG, TCT GGT TAT TGG CCT
CGG TG, TCT TCC AAT ATC GCC ATC TC, and GCG CAC AGA AGC
AGG CAG. Sequence alignments, BLAST searches, and other analyses
were performed by using CLC MAIN 6 software.
Generation of cDNA libraries of UL128 transcripts. Total cell RNA
samples from HFFF cultures infected at a multiplicity of infection (MOI)
of 3 were extracted 72 h postinfection by using an RNeasy plus universal
kit (Qiagen) according to the manufacturer’s instructions. cDNAs were
generated using a NanoScript Precision reverse transcriptase kit (Primer
Design). cDNAs were then amplified using primers UL128F (CATAAAC
GTCAACCACCC) and UL128R (CACTGCAGCATATAGCCC) with the
HiFi expand PCR system (Roche) under the conditions stated above.
Bioinformatics analysis.Analysis ofUL128 splice siteswas carried out
by using NNsplice v. 0.9 (57), NetGene2 (58), SplicePort (59), and Hu-
man Splicing Finder v. 2.4.1 (60). Protein structure prediction was per-
formed using Phyre 2 (61).
Preparation of virus stocks.Where feasible, virus stocks were gener-
ated in RPE-1 cells to prevent the selection of mutations in UL128L. Mer-
lin strainsmutated inUL128L and FIXwere grown inHFFF cells owing to
their inability to spread productively in RPE-1 cells. Supernatant from
infected cell cultures was collected and centrifuged at 470 g for 5 min at
room temperature to pellet cellular debris. Cleared supernatants were
centrifuged at 30,000  g for 2 h at 20°C. Pelleted virions were resus-
pended in DMEM containing 10% fetal bovine serum (FBS) and stored at
80°C.
Gradient purification of virions. Virions were purified from nonin-
fectious enveloped particles, dense bodies, and cellular debris by ultracen-
trifugation through glycerol-tartrate positive-density, negative-viscosity
gradients, as described previously (62, 63). The gradients were centrifuged
at 90,465.7 g for 45min at 20°C. Virions were recovered by piercing the
tubes using a 20-gauge needle and syringe, diluted in 0.04 M sodium-
phosphate buffer (pH 7.4), and pelleted by centrifugation at 90,465.7 g
for 1 h at 20°C. The virion pellet was resuspended in amedium suitable for
downstream applications (see below).
Western blot analysis. Purified virions were resuspended in Nu-Page
LDS sample buffer, and proteins were separated by using a Nu-page Tris-
acetate gel system (Invitrogen) according to the manufacturer’s instruc-
tions. Electrophoresed proteins were subsequently transferred to Hy-
bond-P polyvinylidene difluoride (PVDF) membranes (GE Healthcare)
by semidry transfer at 10 V for 1 h using carbonate transfer buffer. The
membranes were incubated for 1 h at room temperature in blocking buf-
fer (PBS containing 0.1% Tween 20 [PBST] plus 5% [wt/vol] fat-free
milk). They were then incubated with primary antibody for 1 h at room
temperature, washed three times with PBST, and incubated with second-
ary antibody for 1 h at room temperature. Antibody was detected by
SuperSignal West Pico (Thermo) using an AutoChemi imaging system
and Labworks software (UVP Bioimaging). Primary antibodies were
mouse-anti pUL128 antibody SURN, provided by Giueseppe Gerna (1:
100), and mouse anti-gB (1:4,000; Abcam). The secondary antibody was
goat anti-mouse horseradish peroxidase (HRP; 1:1,000; GE Healthcare).
RESULTS
Growth properties of HCMV strains FIX, Merlin, TB40-BAC4,
and TR in fibroblast cells.Clinical isolates of HCMV consistently
replicate inefficiently in fibroblast cultures until mutations arise
and are selected, first in RL13 and then in UL128L (37, 38). A
defect in any of UL128, UL130, or UL131A suppresses formation
of the pentameric glycoprotein complex (gH/gL/UL128L) in the
virion (37). To establish the growth characteristics of virus lacking
or containing gH/gL/UL128L, viruses derived from two Merlin
BAC variants were used in this study.Merlin-UL128Lmut contains
a premature stop codonmutation inUL128 that was selected dur-
ing growth of Merlin in fibroblasts prior to BAC cloning. This
mutation was repaired in Merlin-UL128Lwt. In addition, because
the FIX and TB40-BAC4 clones contain mutations in RL13 (38),
which invariably mutates upon passage in fibroblast or epithelial
cells (37, 38), a preexisting RL13 frameshift mutation present in
these Merlin BACs was not repaired. TR contains an intact RL13,
which could contribute to the growth characteristics of this virus.
However, given the speed with which mutants are consistently
selected in RL13 when clinical virus is grown in vitro (37, 38), it
seems likely that RL13 is either not expressed or is nonfunctional
in virus derived from TR.
Interestingly, all three protein-coding regions in UL128L ap-
pear to be intact in the TB40-BAC4, FIX, and TR BACs, yet recon-
stituted viruses have not been reported to acquire obvious muta-
tions during passage in fibroblasts. It is possible that these three
BACs contain natural variants of UL128L that are stable in fibro-
blasts, or that subtle UL128L mutations have been selected that
preserve the integrity of the protein-coding regions but suppress
their functions. Unfortunately, the clinical samples from which
these strainswere derived are not available for comparison. There-
fore, we compared the growth properties of TB40-BAC4, FIX, and
TR to those of Merlin-UL128Lwt and Merlin-UL128Lmut. To
monitor infection, all viruses were engineered to express EGFP
from an IRES inserted downstream from UL122 (encoding IE2)
(Table 1).
Sequence Variation in HCMV UL128L
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UL128L mutants can arise within a single passage of wild-
type HCMV in fibroblasts (43). To ensure that the experiments
were initiated using genetically homogenous virus prepara-
tions, HFFF cells were transfected with infectious BAC clones
of each virus. The capacity of virus infection to progress by
cell-to-cell spread was assessed by direct measurement of
plaque sizes formed under a semisolid overlay (Fig. 1A). In this
assay, Merlin-UL128Lmut consistently generated the largest
plaques, whereas TB40-BAC4 and FIX plaques were smaller
than those of Merlin-UL128Lmut but were 4- to 2.5-fold larger,
respectively, than those of Merlin-UL128Lwt. TR produced the
smallest plaques of all viruses tested.
Consistentwith previouswork (38),Merlin-UL128Lmut spread
through the HFFF monolayer the fastest (Fig. 1B) and produced
the greatest amounts of cell-free virus (Fig. 1C), whereas Merlin-
UL128Lwt spread the slowest and produced the lowest cell-free
titers (approximately 1,000-fold less than Merlin-UL128Lmut).
Compared toMerlin-UL128Lwt, TB40-BAC4 and FIX each spread
through the HFFF monolayer faster and produced much higher
yields (1,000- and 50-fold, respectively) of cell-free virus. Indeed,
the amount of cell-free TB40-BAC4 release was similar to that of
Merlin-UL128Lmut. The TR infections spread very slowly at first,
but the rate increased from week 5. Like TB40-BAC4 and FIX, TR
also produced peak titers of cell-free virus that exceeded those of
Merlin-UL128Lwt by more than 100-fold.
Thus, TB40-BAC4 and FIX displayedmore efficient cell-to-cell
spread in fibroblasts and produced greater yields of cell-free virus
than Merlin containing wild-type UL128L. Cell-to-cell spread of
TR in fibroblasts was reduced compared to that ofMerlin contain-
ing wild-type UL128L, yet peak cell-free titers were significantly
higher.
TABLE 1 BAC-cloned and recombinant HCMV strains used in this study
Strain Reference UL128L origina
GenBank
accession no. Designation in text
BAC cloned
Merlinb 38 Mutated: GA in UL128 at nt
176260 (Rstop)
GU179001.1 Merlin-UL128Lmut
Merlinb 38 Native GU179001.1 Merlin-UL128Lwt
TRb 51 Native AC146906.1 TR
TB40-BAC4 48 Native EF999921.1 TB40-BAC4
FIXb 50 Native AC146907.1 FIX
Clinical sample (nonpassaged)
3301 40 Native GQ466044.1 3301
Recombinant Merlin containing variant UL128L
Merlin 3301 Merlin-UL128L3301
Merlin TR Merlin-UL128LTR
Merlin TB40-BAC4 Merlin-UL128LTB40
Merlin FIX Merlin-UL128LFIX
Recombinant Merlin strains containing unique substitutions in UL128L
Merlin TB40-BAC4: GT in UL128
at nt 176663 (near splice
acceptor site)
Merlin-UL128GT
Merlin FIX: AG in UL130 at nt
177364 (S72P)
Merlin-UL130AG
a Nucleotide positions are relative to the sequence of BAC-cloned HCMV strain Merlin (GU179001).
b GenBank accession numbers for parental viruses are NC_006273 (Merlin), GU179289 (VR1814; parental virus of FIX), and KF021605 (TR).
FIG 1 Growth characteristics of BAC-cloned strains in fibroblasts. (A) HFFF
cells were transfected with BACDNA for the indicated viruses and then placed
under semisolid overlay. Plaque sizes were measured 2 weeks later. Means and
standard deviations are shown. (B) HFFF cells were transfected with BAC
DNA for the indicated viruses, and infection was allowed to progress until the
monolayer was destroyed. At weekly time points posttransfection (p.t.), the
level of infectionwas estimated by FACS analysis of EGFP-expressing cells. (C)
Supernatants from the infections shown in panel B were retained at weekly
intervals and titrated on HFFFs to provide a measure of cell-free virus release.
(Where indicated, samples were compared by 1-way analysis of variance
[ANOVA] followed by Dunnett’s posttest to compare each sample to Merlin-
UL128wt. *, P 0.05; **, P 0.01; ***, P 0.001).
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Growth properties of HCMV strains FIX, Merlin, TB40-
BAC4, and TR in epithelial cells. In order to investigate the
growth characteristics of FIX, Merlin, TB40-BAC4, and TR in an
epithelial cell line (which requires UL128L for efficient infection),
RPE-1 cells were transfected with the infectious BAC clones. In
marked contrast to the findings for fibroblasts, Merlin-UL128Lwt
displayed much more efficient plaque formation than Merlin-
UL128Lmut (Fig. 2A). TB40-BAC4 and TR plaques were of an
intermediate size (approximately 6 times smaller than Merlin-
UL128wt), while FIX formed plaques that were 25 times smaller,
similar to those produced byMerlin-UL128Lmut. TB40-BAC4 and
TR each spread throughout the RPE-1 monolayer much more
slowly than Merlin-UL128Lwt (Fig. 2B and C) yet produced 100-
to 150-fold higher titers of cell-free virus. Neither FIX norMerlin-
UL128Lmut supported significant spread through RPE-1 mono-
layers.
Thus, the growth phenotypes displayed by TB40-BAC4, FIX,
and TR in fibroblasts and epithelial cells were distinct from those
of Merlin containing wild-type UL128L. Cell-to-cell spread of
TB40-BAC4 and FIX was more efficient in fibroblasts but less
efficient (along with TR) in epithelial cells. TB40-BAC4, TR, and
FIX all produced significantly higher cell-free titers than Merlin-
UL128Lwt in both cell types.
The differential growth characteristics of TB40-BAC4 and
FIX are determined by UL128L. To assess whether the growth
characteristics of each strain could be attributed to UL128L, we
replaced UL128L in Merlin with that from TB40-BAC4, FIX, or
TR, thereby generating the recombinant viruses Merlin-
UL128LTB40, Merlin-UL128LFIX, and Merlin-UL128LTR, respec-
tively (Table 1). Compared to Merlin-UL128Lwt, acquisition of
TB40-BAC4or FIXUL128Lwas consistently associatedwith a 2.5-
to 3-fold increased plaque size in fibroblasts (Fig. 3A), an in-
creased rate of cell-free spread (Fig. 3B), and approximately 10-
fold increased yields of cell-free virus (Fig. 3C). In contrast, TR
UL128L did not alter the rate of cell-to-cell spread of strainMerlin
and produced titers of cell-free virus that were comparable to
those of Merlin-UL128Lwt, at least until week 6 posttransfection.
However, production of cell-free virus by Merlin-UL128LTR in-
creased dramatically by week 7. DNA sequencing of UL128L from
cell-free virus during the final time point revealed that all viruses
retained their original sequence in UL128L, with the exception of
Merlin-UL128LTR. Merlin-UL128LTR harbored a deletion (nt
176742 to 177247) affecting both UL130 and UL128, as well as a
G-to-A mutation at nt 177355 that resulted in a premature stop
codon in UL130. Thus, the rapid increase in cell-free virus pro-
duction by Merlin-UL128LTR was correlated with mutation of
UL128L.
Measurement of the size of plaques formed by these recombi-
nant viruses in RPE-1 cells (Fig. 3D) revealed that expression of
TB40-BAC4 and FIX UL128L reduced the epithelial cell-to-cell
spread ofMerlin, with plaques 2.5 to 7 times smaller, respectively.
However, TR UL128L did not affect the growth characteristics of
Merlin. Likewise, time course experiments in epithelial cells
showed that transfer of FIX UL128L resulted in reduced speed of
dissemination, and transfer of FIX and TB40-BAC4, but not TR,
UL128L resulted in 10- to 20-fold increased production of cell-
free virus (Fig. 3E and F). Thus, compared to Merlin-UL128Lwt,
the ability of TB40-BAC4 and FIX to produce larger plaques in
fibroblasts but smaller plaques in epithelial cells, as well as to pro-
duce higher titers of cell-free virus in both cell types, appears to be
attributable at least in part to genetic differences inUL128L.How-
ever, the differential growth characteristics between TR and Mer-
lin-UL128Lwt appear to be independent of UL128L.
A single-nucleotide difference in a UL128 intron increases
cell-free virus production. TB40-BAC4 infection produced sig-
nificantly higher titers of cell-free virus than Merlin-UL128Lwt in
both epithelial and fibroblast cells. Since UL128L clearly makes a
major contribution to the differential growth characteristics of
TB40-BAC4, we hypothesized that UL128L had acquired a muta-
tion during passage that is compatible with growth in fibroblasts
yet permits the virus to retain a degree of epithelial cell tropism. If
this were the case, any such mutation would be expected to be
unique to TB40-BAC4. UL128L sequences from different strains
exhibit a high level of sequence conservation (92.3% at the nu-
cleotide level [64, 65]); however, BLAST searches revealed that
TB40-BAC4 had a unique G-to-T (GT) substitution at nt
176612 (with reference to the equivalent location in the Merlin
BAC genome). The G residue is conserved in 50 other HCMV
strains and is located in the first of the two UL128 introns, 6 nt
from the splice acceptor site. To determine whether this substitu-
tion affects the growth properties of TB40-BAC4, it was intro-
duced into Merlin-UL128Lwt to generate Merlin-UL128GT (Ta-
ble 1). As an additional control, UL128L from strain 3301 was
inserted intoMerlin (generatingMerlin-UL128L3301). Strain 3301
had not been subjected to in vitro passage prior to sequencing and
FIG 2 Growth characteristics of BAC-cloned strains in epithelial cells. (A)
RPE-1 cells were transfected with BACDNA for the indicated viruses and then
placed under semisolid overlay. Plaque sizes were measured 3 weeks later.
Means and standard deviations are shown. (B) RPE-1 cells were transfected
with BACDNA for the indicated viruses, and infectionwas allowed to progress
until the monolayer was destroyed. At weekly time points, cells were
trypsinized and the level of infection wasmeasured by FACS analysis of EGFP-
expressing cells. (C) Supernatants from the infections shown in panel B were
retained at weekly intervals and titrated on HFFFs to provide a measure of
cell-free virus release. (Where indicated, samples were compared by 1-way
ANOVA followed by Dunnett’s posttest to compare each sample to Merlin-
UL128wt. *, P 0.05; **, P 0.01; ***, P 0.001).
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was thus representative of a UL128L sequence that was different
from that of Merlin but that was known to be wild type. UL128L
from 3301 was also highly homologous to UL128L from TB40-
BAC4 (99.49%at the nucleotide level); however, it did not contain
the GT nucleotide difference identified in the intron of UL128.
Therefore, it was useful to determine whether the GT substitu-
tion, as opposed to natural strain variation elsewhere, contributed
to the different characteristics of UL128L from TB40-BAC4 com-
pared to that from Merlin.
Merlin-UL128Lwt and Merlin-UL128L3301 displayed similar
cell-cell spread properties in RPE-1 cells. Transfer of the substitu-
tion identified in TB40-BAC4 UL128 was sufficient to reduce
epithelial cell-to-cell spread ofMerlin to the same degree (approx-
imately 2-fold) as transfer of the entire TB40-BAC4 UL128L (Fig.
4A). Investigations of infection kinetics (Fig. 4B) and production
of cell-free virus in epithelial cell culture (Fig. 4C) also showed that
Merlin-UL128L3301 had growth characteristics similar to those of
Merlin-UL128Lwt. Transfer of theGT substitution toMerlin did
not alter the rate of spread through the monolayer, but it did
increase the production of cell-free virus by Merlin by the same
degree as transfer of the entire TB40-BAC4 UL128L (approxi-
mately 50-fold). When plaque sizes were measured in fibroblasts
(Fig. 4D), Merlin-UL128L3301 again formed plaques of sizes com-
parable to those ofMerlin-UL128Lwt, whereas the plaques formed
byMerlin-UL128GT were similar in size to those formed byMer-
lin-UL128LTB40 and were consistently 2-fold larger than those
formed by Merlin-UL128Lwt and Merlin-UL128L3301.
A single-nucleotide difference in a TB40 UL128 intron re-
duces splicing efficiency. The proximity of the GT substitution
in TB40-BAC4 UL128 to the splice acceptor site in intron 1 sug-
gested that it had the potential to disrupt splicing of UL128
mRNA. Indeed, bioinformatics analysis predicted that this would
be the case (Fig. 5A). Total infected cell RNA was extracted 72 h
postinfection, and RT-PCR was performed across both introns of
UL128 (Fig. 5B). Three differently spliced products were detected,
and DNA sequencing demonstrated that they corresponded to (i)
an unspliced transcript (656 to 662 bp, depending on the strain),
(ii) a transcript with intron 2 excised (540 bp), and (iii) a tran-
script with both introns 1 and 2 excised (417 bp). All three UL128
products were detected in all strains tested; however, in the con-
structs containing the GT substitution (TB40-BAC4, Merlin-
UL128LTB40, and Merlin-UL128GT), the cDNAs corresponding
to the fully spliced transcript were present at significantly lower
abundance.
Thus, the GT substitution identified in TB40-BAC4 reduced
the efficiency of UL128 mRNA splicing and appeared to be en-
tirely responsible for the different growth characteristics con-
ferred by TB40-BAC4 UL128L compared to those of Merlin
UL128L.
A single-nucleotide difference in FIX UL130 increases virus
production. BLAST searches of UL128L sequences also revealed a
unique A-to-G (AG) substitution in FIX UL130 at nt 177364
(with reference to the Merlin BAC sequence). This difference
manifests as a serine-to-proline amino acid change (S72P), and
according to protein structure prediction, it disrupts a beta sheet
within the protein. The alteration was introduced into Merlin-
UL128Lwt (generating Merlin-UL130AG) (Table 1). Merlin-
UL130AG produced plaques in RPE-1 cells approximately 3-fold
smaller than those ofMerlin-UL128Lwt but similar in size to those
formed by Merlin-UL128LFIX (Fig. 6A). The effects of this substi-
tution on dissemination during infection (Fig. 6B) and cell-free
virus production (Fig. 6C) in epithelial cell culture were also in-
vestigated. It reduced the rate of dissemination through the epi-
thelial cell monolayer compared to that of Merlin-UL128Lwt, al-
though not as much as transfer of the entire FIX UL128L. It also
FIG 3 Growth characteristics of recombinant Merlin viruses containing
UL128L from other strains. HFFF (A) or RPE-1 (D) cells were transfected with
BAC DNA for the indicated viruses and then placed under semisolid overlay.
Plaque sizes were measured 2 (A) or 3 (D) weeks later. Means and standard
deviations are shown. HFFF (B) or RPE-1 (E) cells were transfected with BAC
DNA for the indicated viruses, and infection was allowed to progress until the
monolayer was destroyed. At weekly time points, the level of infection was
estimated from EGFP expression (B), or cells were trypsinized and the level of
infection wasmeasured by FACS analysis of EGFP-expressing cells (E). (C and
F) Supernatants from the infections shown in panels B and E were retained at
weekly intervals and titrated on HFFFs to provide a measure of cell-free virus
release. (Where indicated, samples were compared by 1-wayANOVA followed
byDunnett’s posttest to compare each sample toMerlin-UL128wt. *, P 0.05;
**, P 0.01; ***, P 0.001.)
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increased the production of cell-free virus approximately 50-fold
compared to that of Merlin-UL128Lwt. As with the rate of spread
through the monolayer, the increase in cell-free release was not as
dramatic as that achieved by transfer of the entire FIX UL128L
(approximately 150-fold). When cell-to-cell spread ability was
tested in HFFFs (Fig. 6D), Merlin-UL130AG and Merlin-
UL128LFIX formed plaques of comparable size, and the plaques
were consistently twice as large as those formed by Merlin-
UL128Lwt.
Thus, the AG substitution in FIX UL130 contributed signif-
icantly to the different growth characteristics of FIXUL128L com-
pared to those of Merlin UL128L.
pUL128 is reduced in TB40-BAC4 and FIX virions. The sub-
stitutions in TB40-BAC4 and FIX UL128L identified above have
the potential to influence the function of gH/gL/UL128L by vari-
ous mechanisms. Impairing the efficiency of RNA splicing in
TB40-BAC4 would be expected to limit expression of full-length
pUL128, and the S72P substitution in pUL130 might reduce the
stable incorporation of pUL130 into gH/gL/UL128L or affect a
functional domain of the complex. Since all five subunits are re-
quired for stable incorporation of gH/gL/UL128L into the virion
(28, 66), alteration of the amounts or structural attributes of any
one component has the potential to affect the levels of the entire
complex incorporated into the virion. To investigate this, levels of
pUL128 were analyzed in HCMV virions purified on glycerol-
tartrate gradients (Fig. 7A), with sample loading normalized to
that of gB. Note that although the epitope recognized by the anti-
UL128 antibody used in this assay is not mapped, any differences
in detection are unlikely to be due to different antibody affinities
for pUL128 from different strains; compared toMerlin, UL128 in
the other strains differed by only one (FIX) or two (TB40-BAC4
and TR) amino acids, while in Merlin viruses containing the sin-
gle-nucleotide substitutions from FIX or TB40-BAC4, pUL128 is
identical to Merlin.
pUL128 was undetectable in Merlin-UL128Lmut but was read-
ily detected in viruses having wild-type UL128L sequences
(Merlin-UL128Lwt and Merlin-UL128L3301). Consistent with TR
UL128L having a similar influence on growth kinetics compared
toMerlin UL128L, TR contained levels of pUL128 that were com-
parable to those in Merlin-UL128Lwt and Merlin-UL128L3301.
FIG 4 Characteristics of virus containing TB40-BAC4 UL128 GT unique
nucleotide. (A) RPE-1 cells were transfected with BAC DNA for the indicated
viruses and then incubated under semisolid overlay. Three weeks later plaque
sizes were measured. Means and standard deviations are shown. (B) RPE-1
cells were transfected with BAC DNA for the indicated viruses, and infection
was allowed to progress until the monolayer was destroyed. At weekly time
points, cells were trypsinized and the level of infection was measured using
FACS analysis of EGFP-expressing cells. (C) Also at weekly time points, super-
natants were kept and titrated onHFFFs to provide ameasure of cell-free virus
release. (D) HFFF cells were transfected with BAC DNA for the indicated
viruses and then placed under semisolid overlay. Two weeks later, plaque sizes
were measured. Means and standard deviations are shown. (Where indicated,
samples were compared by 1-way ANOVA followed by Dunnett’s posttest to
compare each sample to Merlin-UL128wt. *, P 0.05; **, P 0.01; ***, P
0.001.)
FIG 5 UL128 gene map and transcripts. (A) The position of the unique A
residue identified in TB40-BAC4 UL128 intron 1, in place of the C residue
present in all other strains, is indicated. Protein-coding exons are shaded. (B)
HFFF cells were infected with the indicated virus, and total RNAwas extracted
at 72 h postinfection. RT-PCR was performed using primers binding in the
first and third exons of UL128. The bands correspond to transcripts that are (i)
unspliced, (ii) lacking intron 2, or (iii) lacking both intron 1 and intron 2.
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However, TB40-BAC4 contained reduced levels of pUL128, as did
Merlin containing either the entire TB40-BAC4 UL128L region
(Merlin-UL128LTB40) or only the GT substitution (Merlin-
UL128GT). pUL128 was undetectable in FIX and Merlin-
UL128LFIX, while Merlin-UL130AG contained reduced, though
detectable, levels of pUL128.
Based on the spread of these viruses in epithelial cells, it seemed
likely that all exceptMerlin-UL128Lmut contained gH/gL/UL128L
in the virion, and that lack of detection of pUL128 in somewas due
to the small amounts of virus loaded in order to keep sample
loading comparable to that of the low-titer viruses Merlin-
UL128Lwt and Merlin-UL128L3301. In a separate blot where the
virion load was not normalized, pUL128L was detectable in all
virions except Merlin-UL128Lmut (Fig. 7B).
Thus, all virions except Merlin-UL128mut contain pUL128;
however, the substitutions identified in UL128L of TB40-BAC4
and FIX resulted in reduced levels of gH/gL/UL128L being incor-
porated into the virion.
TB40-BAC4 and FIXUL128L bestow impaired epithelial cell
tropism. Since gH/gL/UL128L is required for efficient infection of
epithelial cells, its reduced incorporation into virions would be
expected to restrict epithelial cell tropism. Viruses derived from
each BAC-cloned strain were plaque titrated on HFFF and RPE-1
cells in parallel (Fig. 8A). For each virus, the titer reported in
RPE-1 cells was normalized to that reported for HFFF cells for the
same virus, thereby quantitating the ability of each virus to infect
epithelial cells relative to its ability to infect fibroblasts. Merlin-
UL128Lmut infected RPE-1 cells approximately 100-fold less effi-
ciently than HFFFs; however, the majority of plaques were repre-
sented by single cells, indicating that cell-to-cell spread was
strongly inhibited. Viruses containingwild-typeUL128L (Merlin-
UL128Lwt and Merlin-UL128L3301) infected RPE-1 cells with
comparable or slightly greater efficiency than they didHFFFs. Like
Merlin-UL128Lwt and Merlin-UL128L3301, TR infected RPE-1
and HFFF cells with similar efficiencies, consistent with these vi-
ruses containing comparable levels of gH/gL/UL128L in virions.
However, infection of RPE-1 cells by TB40-BAC4 was approxi-
FIG 6 Growth characteristics of virus containing the FIX UL130 AG sub-
stitution. (A) RPE-1 cells were transfected with BAC DNA for the indicated
viruses and incubated under semisolid overlay. Plaque sizes were measured 3
weeks later. Means and standard deviations are shown. (B) RPE-1 cells were
transfectedwith BACDNA for the indicated viruses, and infectionwas allowed
to progress until the monolayer was destroyed. At weekly time points, cells
were trypsinized and the level of infection was measured by FACS analysis of
EGFP-expressing cells. (C) Supernatants from the infections shown in panel B
were retained atweekly intervals and titrated onHFFFs to provide ameasure of
cell-free virus release. (D) HFFF cells were transfected with BAC DNA for the
indicated viruses and then placed under semisolid overlay. Plaque sizes were
measured 2 weeks later. Means and standard deviations are shown. (Where
indicated, samples were compared by 1-way ANOVA followed by Dunnett’s
posttest to compare each sample toMerlin-UL128wt. *, P 0.05; **, P 0.01;
***, P 0.001.)
FIG7 Virion pUL128 content of BAC-cloned strains and recombinantMerlin
viruses. (A) Stocks of the indicated viruses were grown, and infectious virions
were purified on glycerol-tartrate gradients before being analyzed by Western
blotting. Loading was normalized to gB levels (upper panel) and stained for
pUL128 (lower panel). (B) The same samples as those used for panel A were
analyzed by Western blotting. However, rather than being normalized to gB
content, virion loads weremaximized to facilitate detection of pUL128 in each
strain.
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mately 10-fold less efficient than infection of HFFFs, whereas the
efficiency of infection of RPE-1 cells by FIX was approximately
100-fold less than that of HFFFs and comparable to a virus lacking
gH/gL/UL128L (Merlin-UL128Lmut).
Like TB40-BAC4, Merlin-UL128LTB40 and Merlin-UL128GT
infected RPE-1 cells approximately 10-fold less efficiently than
HFFFs (Fig. 8B), displaying a lower infection efficiency thanMer-
lin-UL128Lwt, Merlin-UL128L3301, and TR.
FIX infected epithelial cells with approximately 100-fold less
efficiency than fibroblasts, and this was closely recapitulated by
Merlin containing FIX UL128L (Fig. 8C). The AG substitution
in FIX UL130 also reduced the ability of Merlin to infect RPE-1
cells, although only by approximately 10-fold.
In summary, the unique nucleotide differences identified in
TB40-BAC4 UL128 and FIX UL130 resulted in a reduction in the
amounts of gH/gL/UL128L incorporated into the virion and a
concomitant reduction in the relative ability of virus to infect ep-
ithelial cells.
DISCUSSION
Previous attempts to propagate wild-type HCMV from clinical
material by passage in vitro in fibroblasts have shown that muta-
tions invariably occur in the viral genome. RL13 mutates first,
followed by UL128L, and following these steps virus grows to
much higher cell-free titers (37, 38). However, the adapted virus
lacks gH/gL/UL128L in the virion envelope; therefore, it does not
efficiently infect cells other than fibroblasts. The single-nucleotide
substitutions identified in UL128L of TB40-BAC4 and FIX may
explain the apparently conflicting fact that these strains retain the
ability to infect endothelial and epithelial cells when passaged on
fibroblasts. gH/gL/UL128L is expressed and is present in virions of
these strains, but the level is reduced. This permits greater release
of cell-free virus and potentially reduces the selective pressure for
further mutations in UL128L.
It is important to determine whether these substitutions rep-
resent natural strain variation or mutations acquired in vitro. The
clinical material from which the strains were derived is not avail-
able; therefore, it is not possible to answer this question directly.
However, the S72P substitution in FIX UL130 is absent from the
passaged parental strain VR1814 (37); thus, it probably occurred
during further passage of VR1814 prior to BAC cloning. Similarly,
the fact that the GT substitution in intron 1 of TB40-BAC4 is
unique to TB40-BAC4 strongly suggests that it was acquired dur-
ing passage in fibroblasts prior to BAC cloning. This mutation is
also absent from the consensus sequence of the parental strain
(TB40/E), which instead contains a unique C207S variation in
UL130. TB40/E is known to comprise a mixture of genomes (48),
and the GT mutation may be present at low levels in this mix-
ture. Nevertheless, the identification of the substitutions in FIX
and TB40-BAC4 demonstrates the importance of comparing viral
genomes to unpassaged virus when determining whether a gene is
wild type in sequence and whether (by extension) the phenotype
of a virus can be assumed to be the same as the clinical virus.
The effect of these substitutions was a reduction in levels of
gH/gL/UL128L in the virion. This manifested in impaired effi-
ciency of epithelial cell entry, an increase in cell-to-cell spread in
fibroblasts but a decrease in cell-to-cell spread in epithelial cells,
and an increase in cell-free release in both cell types. Taken to-
gether, these observations indicate that the level of gH/gL/UL128L
in the virion is directly related to its ability to inhibit replication in
fibroblasts and to promote entry and cell-to-cell spread in epithe-
lial cells. Surprisingly, it also suggests that wild-type UL128L in-
hibits the production of cell-free virus in both epithelial and fibro-
blast cells. Themechanismbywhich this occurs is unclear butmay
be related to the fact that gH and gL are common to two glycopro-
FIG 8 Relative infection efficiency of fibroblast and epithelial cells. Stocks of
the indicated viruses were simultaneously titrated onto HFFF or RPE-1 cells.
Titers for each virus on RPE-1 cells were then normalized to the titer of the
same virus on HFFF cells, which was arbitrarily set to 1, giving the relative
efficiency of infection of epithelial cells for each strain. The data are based on
two independent experiments. (A) Relative infection efficiencies of TR, TB40-
BAC4, and FIX compared to various Merlin viruses. (B) Relative infection
efficiencies of Merlin containing either the entire UL128L or the substitution
fromTB40-BAC4 compared to TB40-BAC4 andMerlin. (C) Relative infection
efficiencies of Merlin containing either the entire UL128L or the single nucle-
otide from FIX compared to FIX and Merlin.
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tein complexes (gH/gL/UL128L and gH/gL/gO). Greater amounts
of gH/gL/UL128L may result in there being less gH/gL available
for the formation of gH/gL/gO. gH/gL/gO may be important for
secondary envelopment of progeny virions and egress into the
supernatant (23) and for subsequent infection by cell-free released
virus (24, 67), explaining the increased titers of cell-free virus as
the level of gH/gL/UL128L is reduced. This model is supported by
the observation that expression of wild-type UL128L reduces lev-
els of both cell-free and cell-associated virus (37), and that loss of
gO results in greater accumulation of gH/gL/UL128L in the virion
with a concomitant increase in cell-to-cell spread in epithelial and
endothelial cells (24).
Although the mutations identified in FIX and TB40-BAC4
strongly contributed to the greater production of cell-free virus
and differences in cell-to-cell spread, it is clear that they are not the
sole reason for the growth differences seen in TB40-BAC4 and FIX
compared to Merlin-UL128Lwt. TB40-BAC4 grew to approxi-
mately 1,000-fold higher cell-free titers than Merlin-UL128Lwt,
whereas transfer of the GT mutation in TB40-BAC4 UL128 re-
sulted in an increase of only 50-fold. Likewise, FIX was unable to
spread cell to cell in RPE-1 epithelial cells, yet Merlin-UL128LFIX
was able to spread, albeit more slowly than Merlin-UL130AG,
which itself spread more slowly than Merlin-UL128Lwt. Similar
considerations apply to TR. Despite containing levels of gH/gL/
UL128L similar to those in Merlin-UL128Lwt, TR generated
higher cell-free titers yet displayed lower efficiency of cell-to-cell
spread in both fibroblast and epithelial cells. The observation that
Merlin-UL128LTR behaved the same as Merlin-UL128Lwt and
Merlin-UL1283301, and that TR UL128L readily mutated when
expressed in the Merlin genome during growth in fibroblasts but
not when expressed within the TR genome, underlines the con-
clusion that the differential growth characteristics of TR were in-
dependent of UL128L yet are sufficient to enhance the stability of
UL128L in vitro. These differences may be due to a number of
other genome regions that can influence growth in a cell type-
specific manner (37, 68–70). Sequence differences in other glyco-
proteins might also be responsible, with gO being a particularly
prominent candidate because it exists in several highly divergent,
yet stable, genotypes (43, 71–73). Alignments of the protein-cod-
ing regions of gH, gL, gM, gN, gO, and gB of TR, TB40-BAC4, and
FIX with those of other strains did not reveal any unique substi-
tutions that could represent in vitro adaptations, although all 3
viruses lack sequences in Us, where the BAC cassette was inserted,
and TB40-BAC4 contains mutations in RL5A, RL6, UL141, and
UL40 (48, 74), and TR contains a mutation in UL97 (C607Y) that
conveys ganciclovir resistance (75). These mutations could also
contribute to the growth characteristics observed.
Owing to its central role in determining tropism for a broad
range of clinically significant cell types, it is essential that an intact,
wild-type gH/gL/UL128L is present in any strain used to investi-
gate HCMV pathogenesis. More recently, other important impli-
cations of UL128L function have underscored the need for re-
search based on virus strains that are competent in this genome
region. Specifically, gH/gL/UL128L elicits a potent neutralizing
antibody response in a natural infection (76–81) and is considered
ideal for inclusion in new vaccine strategies (34, 82). The differ-
ences identified between levels of gH/gL/UL128L in various
strains analyzed have the potential to affect read-outs of the effi-
cacy of anti-gH/gL/UL128L antibodies. However, they also offer
significant advantages relating to the important issue of being able
to grow HCMV while minimizing the risk of mutation. For work
performed in fibroblast cells, viruses based onMerlin-UL128Lmut
offer an ideal defined, full-length genome that produces relatively
high titers. For work requiring infection of other cell types, Mer-
lin-UL128GT produces larger amounts of cell-free virus that is
still able to infect epithelial and endothelial cells, potentially with
reduced risk of mutation in UL128L.
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